Phase 1 Oral QPX7831 SAD and MAD in Healthy Adults

STATUS

Recruiting
End date

Nov 1, 2022
participants needed

78
sponsor

Qpex Biopharma, Inc.

Send

Updated on 5 May 2022

See if I qualify

body mass index

tubal ligation

hysterectomy

beta-lactamase inhibitor

electrocardiograms

Accepts healthy volunteers

Summary

This Phase 1 study will assess the safety, tolerability, and pharmacokinetics (PK) of QPX7831, a beta-lactamase inhibitor, when administered orally in single ascending doses and in multiple ascending doses to heathy adult subjects.

Description

Qpex Biopharma, Inc. is developing an oral dosage form that delivers QPX7728, a new boron-based beta-lactamase inhibitor with activity against both serine and metallo-beta-lactamases, for oral treatment in combination with a beta-lactam antibiotic.

The objectives are:

To assess the safety and tolerability of QPX7831 when administered orally in single ascending doses (SAD) and in multiple ascending doses (MAD) to healthy adult subjects.
To assess the PK of single and multiple doses of oral QPX7831 when administered to healthy adult subjects to determine if the target exposures identified in preclinical studies can be attained in healthy adult subjects.

Details

Condition	Bacterial Infections
Treatment	Placebo Comparator, QPX7831
Clinical Study Identifier	NCT04578873
Sponsor	Qpex Biopharma, Inc.
Last Modified on	5 May 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Healthy adult males and/or females of non-childbearing potential, 18 to 55 years of age (inclusive) at the time of screening
	Body mass index (BMI) ≥ 18.5 and ≤ 29.9 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive)
	Medically healthy with clinically insignificant screening results (e.g., laboratory profiles, medical histories, electrocardiograms [ECGs], physical examination) as assessed by the PI
	Voluntarily consent to participate in the study
	Male volunteers must agree to use a condom when engaging in any sexual activity from study check-in through 30 days following the last administration of the study drug, and to not donate sperm during this same period of time. If engaging in sexual activity with a female partner of childbearing potential, an additional method of birth control must be used. Approved additional methods of birth control include
	Intra-uterine device (IUD) in place for at least 3 months prior to Day 1 through 30 days following the final dosing of the study drug
	Barrier method (diaphragm) for at least 14 days prior to Day 1 through 30 days following dosing of the study drug
	Stable hormonal contraceptive for at least 3 months prior to Day 1 through 30 days following dosing of the study drug
	Surgical sterilization (vasectomy) at least 6 months prior to Day 1
	Females of non-childbearing potential with serum FSH levels ≥ 40 mIU/mL are either
	Bilateral tubal ligation
	postmenopausal (defined as 12 months spontaneous amenorrhea) or have undergone
	Hysterectomy
	one of the following sterilization procedures at least 6 months prior to Day 1
	Hysterectomy with unilateral or bilateral oophorectomy
	(and is documented)
	Bilateral oophorectomy
Exclusion Criteria
	History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease
	Positive urine drug/alcohol testing at screening or check-in (Day -1)
	Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV)
	History or presence of alcoholism or drug abuse within the 2 years prior to Day 1
	Use of more than 5 packs/week of cigarettes (or equivalent amount of nicotine-containing product) within 6 months prior to Day 1. Subjects must agree to refrain from smoking for the duration of the study
	Excessive intake of alcohol, defined as an average daily intake of greater than 2 standard drinks for women and 4 standard drinks for men; 1 bottle of beer (375mL) is equivalent to approximately 1.4 standard drinks, 1 glass of spirits (30mL) is equivalent to approximately 1 standard drink and 1 glass (150mL) of wine is equivalent to approximately 1.5 standard drinks
	Use of any prescription medication (with the exception of hormone replacement therapy for females) within 14 days prior to Day 1
	Use of any over the counter (OTC) medication, including herbal products, probiotics and vitamins, within the 7 days prior to Day 1. Up to 2 grams per day of paracetamol is allowed for acute events at the discretion of the PI
	Use of antacids, H2 receptor blockers or proton pump inhibitors within 7 days prior to Day 1
	Documented hypersensitivity reaction or anaphylaxis to any medication
	Blood donation or significant blood loss (i.e., > 500 mL) within 56 days prior to Day
	Plasma donation within 7 days prior to Day 1
	Participation in another investigational clinical trial within 30 days prior to Day 1 or within 5 half-lives of the previous investigational drug, whichever is longer
	Females who are pregnant or lactating
	Surgery within the past three months prior to Day 1 determined by the PI to be clinically relevant
	Any acute illness within 30 days prior to Day 1
	QTcF interval >450 msec for males and >470 for females or history of prolonged QT syndrome at screening or check-in (Day -1)
	Calculated creatinine clearance less than 80 mL/min (Cockcroft-Gault method) at screening or check-in (Day -1)
	Subjects who have any clinically significant abnormalities on laboratory values at screening or check-in (Day -1), in particular
	White blood cell count < 3,000/mm3, hemoglobin < 11g/dL
	Absolute neutrophil count < 1,200/mm3 or platelet count < 120,000/mm3
	Liver function abnormalities at screening or check-in (Day -1) (defined by an elevation in bilirubin, AST or ALT 1.5 x ULN of the normal range for subjects based on age and sex)
	Any other condition or prior therapy, which, in the opinion of the PI, would make the
	subject unsuitable for this study

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

0/250

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

body mass index

tubal ligation

hysterectomy

beta-lactamase inhibitor

electrocardiograms

Accepts healthy volunteers

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Phase 1 Oral QPX7831 SAD and MAD in Healthy Adults